Veradermics (MANE) Liabilities and Shareholders Equity (2024 - 2026)

Veradermics has reported Liabilities and Shareholders Equity for 3 years, with the latest figure at $397.4 million in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity changed N/A year-over-year to $397.4 million; the trailing twelve-month figure through Mar 2026 stood at $605.5 million (changed N/A YoY), and the FY2025 full-year result was $152.6 million, up 174.82% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $397.4 million, up from $152.6 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $397.4 million in Q1 2026, with the low at $55.5 million in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $201.8 million across 3 years, with a median of $152.6 million in 2025.
• The largest YoY upside for Liabilities and Shareholders Equity was 174.82% in 2025 against a maximum downside of 174.82% in 2025.
• Veradermics' Liabilities and Shareholders Equity stood at $55.5 million in 2024, then soared by 174.82% to $152.6 million in 2025, then jumped by 160.36% to $397.4 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $397.4 million (Q1 2026), $152.6 million (Q4 2025), and $55.5 million (Q4 2024), per Business Quant data.